A case of readministration of nivolumab by treating with apremilast for psoriasiform eruption as irAE

A case of readministration of nivolumab by treating with apremilast for psoriasiform eruption as irAE

Bibliographic Details
Main Authors:	Naohisa Ichiki, Toshiaki Tanabe, Satoko Hisada, Miho Sugata, Yumi Ito, Tomonori Komatsu, Masanori Kodera
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-06-01
Series:	Journal of Cutaneous Immunology and Allergy
Online Access:	https://doi.org/10.1002/cia2.12157

Similar Items

Readministration of adenoviral gene delivery to dopamine neurons.
by: Gonzalez, S, et al.
Published: (2007)

Hyperacute Radiation Pneumonitis after Severe irAE
by: Yang Chou, et al.
Published: (2024-04-01)

Review of Immune-Related Adverse Events (irAEs) in Non-Small-Cell Lung Cancer (NSCLC)—Their Incidence, Management, Multiorgan irAEs, and Rechallenge
by: Raju Vaddepally, et al.
Published: (2022-03-01)

Editorial: Immune-related adverse Events (irAEs) of biopharmaceuticals
by: Alexander Batista-Duharte, et al.
Published: (2023-05-01)

4401 Incidence, management, and outcomes of immune-related adverse events (irAEs): an analysis of a multidisciplinary toxicity team for cancer immunotherapy related irAEs
by: Aanika Balaji, et al.
Published: (2020-06-01)

Readministration of Cancer Drugs in a Patient with Chemorefractory Metastatic Colorectal Cancer
by: Tetsuro Kawagoe, et al.
Published: (2020-01-01)

A case of sialadenitis observed as an irAE of atezolizumab: A case report
by: Kosumi Kumagai, et al.
Published: (2024-01-01)

B cell focused transient immune suppression protocol for efficient AAV readministration to the liver
by: Jyoti Rana, et al.
Published: (2024-03-01)

A case of malignant melanoma with shrinking metastases after sequential severe irAEs
by: Aya Maekawa, et al.
Published: (2020-04-01)

Successful Readministration of AAV8 Following Administration of Nondepleting CD4 Antibody at the Time of Vector Administration
by: McIntosh, J, et al.
Published: (2006)

Pityriasis Rosea Presenting as Psoriasiform Plaque
by: Abhijit Saha, et al.
Published: (2024-01-01)

Psoriasiform dermatoses: the diagnostic challenges revisited
by: Shruti Bhargava, et al.
Published: (2022-04-01)

Psoriasiform Skin Lesions and Dental Abnormalities
by: Huda Al Maqbali, et al.
Published: (2024-05-01)

Molecular Mechanisms of Cutaneous Immune-Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitors
by: Yi-Shan Teng, et al.
Published: (2023-07-01)

Apremilast Cocrystals with Phenolic Coformers
by: Yelizaveta Naumkina, et al.
Published: (2024-12-01)

Repigmentation of Tenacious Vitiligo on Apremilast
by: Sara B. Huff, et al.
Published: (2017-01-01)

Psychiatric risk profile of apremilast
by: Mustafa Ekici, et al.
Published: (2024-07-01)

1245 Th17 and Type 2 CD8+ cytokine signatures predict irAEs in solid tumors
by: Evan J Lipson, et al.
Published: (2023-11-01)

Development of an eHealth Tool for Capturing and Analyzing the Immune-related Adverse Events (irAEs) in Cancer Treatment
by: Saeed Moradian, et al.
Published: (2023-06-01)

Psoriasiform paradojic reaction associated with infliximab infusion
by: Lorena De Agustín Sierra
Published: (2017-07-01)

Psoriasiform Dermatitis in a COVID-19 Patient
by: Marlyn Wu, et al.
Published: (2022-01-01)

Psoriasiform Drug Eruption Associated with Sodium Valproate
by: Gulen Gul Mert, et al.
Published: (2013-01-01)

Clinico-histomorphological study of psoriasis and Psoriasiform dermatitis
by: Shagun Gupta, et al.
Published: (2023-07-01)

Is apremilast a treatment for SAPHO syndrome?
by: Ju Zhang, et al.
Published: (2024-12-01)

Clinical experience with apremilast for psoriatic arthritis
by: E. Yu. Loginova, et al.
Published: (2018-09-01)

Safety of apremilast: risk of psychical disorders
by: T. M. Bukatina, et al.
Published: (2018-02-01)

Zinc Supplementation for Acrodermatitis Enteropathica Overlapped with Psoriasiform Lesions
by: Wang L, et al.
Published: (2024-11-01)

Cladribine Ameliorates Imiquimod Induced Murine Psoriasiform Dermatitis
by: Xue J, et al.
Published: (2025-02-01)

A case of psoriasiform drug eruption caused by temozolomide
by: Tokuko Oguro, et al.
Published: (2022-10-01)

Case report: Treatment of psoriasiform dermatitis in patients with malignancy
by: Jinzhu Mao, et al.
Published: (2024-04-01)

Psoriasiform rash after initiation of treatment with olanzapine and carbamazepine.
by: M. Abdelkefi, et al.
Published: (2023-03-01)

A case of psoriasiform graft-versus-host disease
by: Jinping HUANG, et al.
Published: (2022-06-01)

A case of psoriasiform syphilid (from clinical practice)
by: S. V. Koshkin, et al.
Published: (2017-08-01)

Crushed apremilast for the treatment of oral lichen planus
by: Penelope Kim-Lim, BS, et al.
Published: (2023-07-01)

Ghrelin attenuates imiquimod‐induced psoriasiform skin inflammation in mice
by: Kazuma Kaneda, et al.
Published: (2019-12-01)

Case of durvalumab‐induced annular psoriasiform dermatitis in lung cancer
by: Asako Ota, et al.
Published: (2022-10-01)

Psoriasiform dermatitis in a person of colour with chronic hepatitis B
by: Paloma A. Seidel, et al.
Published: (2024-07-01)

Mechanisms and Effects of Isorhamnetin on Imiquimod-Induced Psoriasiform Dermatitis in Mice
by: Chieh-Shan Wu, et al.
Published: (2022-12-01)

Ocrelizumab‐induced psoriasiform dermatitis: Case reports and review of the literature
by: Natalia Naranjo Guerrero, et al.
Published: (2023-12-01)

Psoriasiform mycosis fungoides–cutaneous T-cell lymphoma in an African American
by: Austinn C. Miller, MD, et al.
Published: (2023-08-01)